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Conflicts of interest exist in dermatology when profes-
sional judgement concerning a primary interest, such as 
research validity, may be influenced by a secondary inte-
rest, such as financial gain from a for-profit organization. 
Conflict of interest is a condition and not a behaviour, 
although there is clear evidence that gifts influence beha-
viour. Little has been written about conflicts of interest 
in dermatology. This series of papers raises awareness 
of the subject by exploring it in greater depth from the 
perspective of a dermatology researcher, an industry re-
searcher, a dermatology journal editor, a health services 
researcher and a patient representative. Collectively, 
they illustrate the many ways in which conflicts can per-
vade the world of dermatology publications and patient 
support group activities. Key words: conflicts of interest; 
dermatology; disease mongering; disease awareness cam-
paigns; ghost authorship.
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1. DefiniTions anD sCope of This arTiCLe
Hywel Williams
Where did it all come from?
The basis of this article arose from a workshop led by 
the European Dermato-Epidemiology Network (EDEN) 
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on the topic of conflict of interest (COI) in dermato-
logy held at the Spring 2006 European Academy of 
Dermato-Venereology meeting in Finland. It might 
strike the reader that the topic of COI was an odd one 
for a meeting that relies so heavily on sponsorship from 
the pharmaceutical industry. Nevertheless, the session 
was well attended and received by a wide range of col-
leagues from academia, clinical practice and industry. 
It was clear from the discussion that ensued from the 
potentially difficult areas surrounding COI in derma-
tology, that some themes relating to COI and dermato-
logy research output needed to be shared more widely 
amongst the dermatology community through a journal 
article. This article therefore represents a compilation 
of those talks, plus an additional contribution about 
COI and patient support groups from ray Jobling, who 
has psoriasis and who has worked with patient support 
groups for many years. 
The compilation is not intended to be a comprehen-
sive or systematic review of the extent and effects of 
COI in dermatology. Instead, the article aims to raise 
awareness of the existence of COI in dermatology, as 
the topic appears to be very rarely, if ever, mentioned 
at dermatology meetings. Even in the dermatological 
literature, I could find only eight relevant publications 
when searching PubMed using the terms {“conflict” 
AND “dermatology”} as of 29th August 2006 (1–8). 
Indeed, I might even go so far as to suggest that COI 
is a taboo subject in dermatology – possibly because 
nobody wants to upset, what may seem to some, a cosy 
relationship. 
The article simply makes some points about the topic 
of COI from a variety of perspectives. many of the 
examples developed refer to psoriasis, which is perhaps 
unsurprising given the current substantial resources 
being put into launching a new range of interesting, but 
also very expensive, new biological treatments for this 
disease. luigi Naldi, a dermato-epidemiologist from 
Italy, begins by lamenting the demise of curiosity-dri-
ven as opposed to financially-driven research. He then 
develops examples of COI from the EDEN psoriasis 
survey, opening our eyes to some of the subtle ways in 
which drugs can be promoted favourably. Carle Paul, 
a dermatologist with many years of experience in the 
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pharmaceutical industry, elaborates on the importance 
of full disclosure and how COI is not just an industry 
problem. He talks about selective publication and the 
dangers of Bodenheimer’s “non-writing author/non-
author writing syndrome”, as well as ways of reducing 
such behaviour in the future. Anders Vahlquist, editor 
of this journal, shares his concerns about COI and 
comments on the extent to which dermatology journal 
editors can and should attempt to tackle the problem. 
The question remains as to whether all this concern 
and intrigue makes any difference to you as the reader? 
Sara Schroter from the British Medical Journal presents 
two key randomized controlled trials that show that the 
presence and type of COI as well as the type of article 
in which it is contained, makes a profound difference 
on the validity that readers place on that article. Finally, 
ray Jobling talks from the perspective of patient support 
groups who are often desperate for funding. He points 
out how such groups sometimes have to wrestle in an 
unequal partnership with big pharmaceutical companies, 
who may view such groups as excellent vehicles for di-
sease awareness campaigns and as legitimate substrates 
for disease mongering.
Although the article raises some uncomfortable 
revelations at times, its overall tenor is one of raising 
awareness of an issue that faces dermatologists on an 
almost daily basis. All contributors have been encoura-
ged to look to the future for developing solutions and 
for getting the balance right.
What is a conflict of interest?
It is important to start by defining the theme on which 
this article is based. Many definitions of COI exist, but 
there is reasonable similarity between those used on 
medical journal websites. I like the definition suggested 
by the British Medical Journal (9): “A competing in-
terest exists when professional judgement concerning 
a primary interest (such as patients’ welfare or the 
validity of research) may be influenced by a secondary 
interest (such as financial gain or personal rivalry)”. 
They later qualify the definition by restricting requests 
for competing interests to financial ones, based on their 
experience that authors often do not disclose them. 
Two important points emerge from this definition. 
The first is that COI is a condition and not necessarily 
a behaviour. It may be said for instance, that dogs gene-
rally chase cats, yet there are plenty of examples of the 
two living together in harmony (Fig. 1). merely being a 
dog does not necessarily mean that a type of behaviour 
(chasing cats) has occurred – it simply means that on 
average a dog will chase (behaviour) a cat because of 
the condition of “being a dog”. In other words, COI 
is a set of circumstances, interests or conditions that 
place the affected person in a position of potentially 
being influenced by those circumstances. It does not 
mean, for example, that if I was paid to fly to Mauri-
tius and was lavishly entertained there in order to give 
a talk about the new biologicals for psoriasis, that I 
would necessarily give a talk that portrayed these new 
treatments in a positive light. Sometimes, people with 
conflicts deliberately overcompensate for potentially 
biased behaviour – for example, the teacher who hap-
pens to have his own son in his class might give his 
son an extra hard time in order to avoid accusations of 
favouritism. The second point to note is that the degree 
to which behaviour has been influenced in relation to 
the declared conflict can only be judged by those in the 
audience. It is not for me, for example, to rationalize 
internally that the trip to Mauritius would not influence 
my portrayal of a new drug developed by those who 
have looked after me so well – the process requires me 
first to declare all possible conflicts at the start of any 
talk and then allow the audience to make a judgement 
about whether my subsequent behaviour was influenced 
by those conflicts. We can rationalize as much as we 
like that we are all above the financial or other tempta-
tions arising from conflicts, but conflicts are conflicts. 
Declaring them does not necessarily imply that you are 
“behaving badly”, but they are a set of conditions that 
are known profoundly to affect human behaviour, and 
as such they must be declared (10–13).
A final point that needs to be emphasized is that COI 
is not just concerned with a polarized debate about clini-
cians and the pharmaceutical industry. As Carle Paul 
later comments, COI can arise from the need to publish 
for the advancement of careers. Human characteristics 
such as jealousy, arrogance and favouritism can pervade 
processes such as peer review, especially if these are 
done anonymously. So COI is all around us – the key 
is to declare it if in doubt and let others decide if it is 
important. As Wazana’s systematic review shows, there 
is now overwhelming evidence that seemingly trivial 
conflicts, such as receiving gifts, affect prescribing be-
haviour (13). I suspect that this article will confirm the 
Fig. 1. Conflict of interest is a condition, not necessarily a behaviour. Dogs 
generally chase cats, but there are plenty of examples of them living together 
harmoniously.
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suspicions of many readers, surprise others, and even 
anger some who might have a lot on their conscience, 
but I hope that, most of all, it will stimulate colleagues 
to think more about COI in the field of dermatology and 
to ensure that checks are in place to keep the balance 
at the right level.
2. More on ConfLiCTs of inTeresT in 
DerMaToLogy
Luigi Naldi
Economic rather than curiosity-driven research
“The most important scientific development of the 
20th century is that economic interests have replaced 
curiosity as a driving force of research activities.” This 
statement from the Nobel Prize winner Kary mullis, 
underlines a central issue when discussing conflict of 
interest (COI) in medicine: a shift in research support 
from that provided by independent sources to that 
provided by the pharmaceutical industry (14). The 
influence of the pharmaceutical industry on medical 
research has increased enormously in the last decades. 
This has been paralleled by heavy marketing compe-
tition. Alarms have been raised repeatedly concerning 
the consequences of the critical dependence of clinical 
research on economic interests. marcia Angell, former 
editor of the New England Journal of Medicine, was 
concerned about the industry becoming “primarily a 
marketing machine” and co-opting “every institution 
that might stand in its way” (15). Richard Horton, 
editor of the Lancet, outlined how journals ”devolved 
into information laundering operations for the pharma-
ceutical industry” (16). Jerry Kassirer, another former 
editor of the New England Journal of Medicine, argued 
that the industry has deflected the moral compasses 
of many physicians (17). There is a cycle of depen-
dency between physicians, academic opinion leaders, 
patient’s organizations, researchers, and industrial 
interests (18). 
Dermatology does not appear to be an exception
As indicated by the European Dermato-Epidemiology 
Network (EDEN) psoriasis project, only a quarter of 
all randomized clinical trials published on psoriasis 
from 1977 to 2000 have been conducted independently 
from direct pharmaceutical company sponsorship, 
and the proportion of sponsored trials is increasing 
dramatically in more recent years (19). randomized 
clinical trials are considered one of the highest forms 
of evidence. A large trial published in a major journal 
has the journal’s stamp of approval (unlike advertising 
material), will be distributed around the world and may 
well receive global media coverage. For a drug com-
pany, a favourable trial published in a good journal is 
worth thousands of pages of advertising (Fig. 2). quite 
remarkably, sponsored trials rarely produce results that 
are unfavourable to the companies’ products. There is 
evidence from systematic reviews that published stu-
dies funded by pharmaceutical companies are several 
times more likely to show results favourable to the 
company than studies funded from other sources (20, 
21). Not surprisingly, data from the EDEN psoriasis 
project showed that the large majority of sponsored 
trials provided positive results. 
There are several ways to obtain the data you want 
from clinical research. Table I presents some examples 
(18). Placebo-controlled randomized trials, the use of 
surrogate outcome measures over a short period of 
time, rather than clinically relevant outcomes over a 
significant time-span, and duplicate publications, are all 
means of enhancing spin on a product, as evidenced in 
the EDEN psoriasis project. These factors may combine 
with selective reporting (22). In spite of the enthusiasm 
Fig. 2. For a drug company, a favourable trial published in a good journal is 
worth thousands of pages of advertising. 
Table I. Examples of techniques for pharmaceutical companies 
to obtain the results they want from clinical trials (from R. Smith, 
modified (18)
•	 Conduct a trial of your drug against a treatment known to be inferior 
(typically placebo even in the presence of active competitors).
•	 Compare your drugs against too low a dose of a competitor drug.
•	 Conduct a trial of your drug against too high a dose of a competitor 
drug (making your drug seem less toxic).
•	 Conduct trials that are too small to show differences from competitor 
drugs.
•	 Use multiple end-points in the trial and select for publication those that 
give favourable results.
•	 Do multicentre trials and select for publication results from centres that 
are favourable.
•	 Conduct subgroup analyses and select for publication those that are 
favourable.
•	 Present results that are most likely to impress – for example, reduction 
in relative rather than absolute risk.
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demonstrated by opinion leaders and the public, the 
development of new biological agents for psoriasis is 
no exception to this situation (23). To date, no long-term 
randomized trials that include active comparators are 
available on these drugs. On the other hand, promotional 
strategies for new biological agents in psoriasis offer 
additional teaching examples of the different modalities 
adopted to expand the market for new drugs using scien-
tific data and statements by opinion leaders in sponsored 
symposia. Patient organizations in sponsored campaigns 
are also used to disseminate information on psoriasis 
management. The establishment of a new “World Pso-
riasis Day”, originally sustained by a pharmaceutical 
company (Serono), is just one example (24). 
Understanding drug promotion
In Italy, recognition of the problems involved with 
new drug registration and lack of data on effectiveness 
and safety in situations where alternative conventional 
treatments are already available, have prompted the 
initiation by the Italian Drug Agency (AIFA) of post-
marketing surveillance programmes closely linking 
prescription to the provision of patient data at first 
drug prescription and on a regular basis subsequently 
during a pre-defined follow-up period. One example 
of such a programme on psoriasis is the Psocare pro-
gramme (25). All the patients receiving a new systemic 
treatment for psoriasis for the first time (including the 
new biological agents) at a number of reference pso-
riasis centres are registered and followed up within the 
programme. During the first eight months of activity 
(as of 4th August 2006) 4302 patients were entered in 
the programme. Interestingly, a number of initiatives 
sponsored by pharmaceutical companies in connection 
with Italian scientific dermatological societies and 
the patient organizations, were started in Italy in an 
obvious attempt to use the Psocare programme as a 
marketing opportunity, illustrating the pervasive nature 
of marketing interests in medical activities. In a typical 
case, an initiative consisted of a drug-sponsored sym-
posium with a presentation of the Psocare system and 
data, followed by several presentations of efficacy and 
safety data concerning the new biological agents, and 
only passing mention of older established conventional 
therapies. In many instances, the label “Psocare” was 
used in the context of these sponsored symposia without 
the permission or agreement of AIFA. 
The industry perspective on drug promotion is bet-
ter understood by reading a document such as the one 
produced by the European Federation of Pharmaceutical 
Companies. The document as reported by liberati et 
al. (26) identifies 20 diseases and conditions, such as 
dementia, asthma, hepatitis C, rheumatoid arthritis and 
osteoporosis, where “potentially achievable benefits are 
not achieved because patients are denied access to im-
portant therapeutic interventions due to poor diagnosis, 
limited patient awareness of effective drugs, and strict 
cost containment by healthcare systems”. Selectivity 
of reporting is the main theme to emerge from the 
document. In the section on Alzheimer’s disease, for 
example, second generation acetyl cholinesterase agents 
are reported as increasing quality of life, with massive 
economic benefits for society. Only one reference (in 
German) is quoted, while systematic reviews pointing 
to inadequate follow-up and questionable end-points are 
omitted. One of the reasons why new drugs are regis-
tered despite a lack of firm evidence concerning their 
actual role in the disease for which they are developed, 
is the limited role played by regulatory agencies (27). 
It should be noted that the European Agency for the 
Evaluation of medical Products (EmEA) is part of the 
Directorate for Enterprise and Industry and not Public 
Health, suggesting a possible COI in the regulatory 
process itself. 
3. an inDusTry researCher’s perspeC-
Tive
Carle Paul
research studies in biomedical journals are under inten-
se scrutiny because of proven examples of misleading 
reports of research findings from both industry-spon-
sored and academic research. Various types of conflict 
of interest (COI) exist for both authors and reviewers: 
publications play a role in career advancement, both in 
academia and in the pharmaceutical industry, leading 
potentially to financial gains. Enhanced reputation 
and media attention are associated with publications 
in reputable journals. The most obvious types of COI 
in industry-sponsored research are financial. Financial 
COI between clinical investigators and the pharmaceu-
tical industry has been associated with a risk of under-
reporting unfavourable study conclusions and with bias 
in reporting positive study results. One study from the 
field of dermatology showed that industry sponsorship 
was significantly associated with higher likelihood of 
reporting positive results, higher methodological qua-
lity and larger clinical trials (3).
Disclosure of potential conflicts of interest 
The prerequisite in evaluating the role of a potential 
financial COI on how research results are reported 
is full disclosure of potential COI. Both authors and 
reviewers of biomedical journals should fully disclose 
potential COI. Although the presence of a potential 
COI does not imply that the research is of lower qua-
lity, it represents important information for the reader. 
Studies have shown that full disclosure of potential 
conflicts is rarely the rule (28). For the reader, iden-
tification of potential COI is not easy if undisclosed. 
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To illustrate this point, I have taken the example of a 
recent paper describing a potential risk of skin cancer 
with calcineurin inhibitors based on in vitro findings 
suggesting a reduction in DNA repair after ultraviolet 
(UV) radiation in keratinocytes exposed to these agents 
(29). No COI are disclosed in this work, which was also 
presented publicly at a Pediatric Advisory Committee 
of the Food and Drug Administration (30). However, 
a visit to the website of the company sponsoring the 
research and from which the authors are employees 
provides interesting results. The research sponsor is a 
bio-pharmaceutical company that develops and markets 
topical prescription and over-the-counter drugs in the 
field of DNA skin repair and photobiology (31). Among 
these is a “skin-cancer repair lotion” containing a DNA 
repair enzyme that is supposed to counterbalance the 
negative effect of UV radiation. Does this financial 
interest represent a true COI? The fact that the manu-
facturer of a DNA repair product may gain advantage 
from potential DNA damage properties of a drug cannot 
be denied. As Williams emphasizes in the introduction 
of the present paper, the readers should be given the 
opportunity to make their own judgements on the re-
levance of such a potential COI. This can only happen 
when the information is made available during the peer 
review process as well as in the publication.
Authorship, responsibility and conflicts of interests
Originally, clinical research was performed predomi-
nantly by academic researchers with little or no sup-
port from the pharmaceutical industry. Since 1970, 
however, a dramatic increase in research funding from 
the pharmaceutical industry has occurred. Clinical 
research teams in the pharmaceutical sector comprise 
physicians specialized in clinical research, clinical 
scientists, methodologists and statisticians, the struc-
ture of which frequently mirrors the organization of a 
large academic centre. most multicentre therapeutic 
studies are now the result of collaborations between 
researchers from the pharmaceutical industry (usually 
referred to as “the industry” in the medical literature) 
and clinical investigators (usually referred to as aca-
demic researchers or investigators). In many papers, 
both industry researchers and academic investigators 
meet the International Committee of medical Journal 
Editors (ICmJE) criteria for authorship (32), having 
made a significant contribution to study design, ana-
lysis, interpretation of results and manuscript writing. 
Concerns have been made recently in writing and many 
times orally to me that industry researchers have an 
increased risk of introducing bias because of vested 
interests in the drug studied (33). Having spent eight 
years in the pharmaceutical industry and about the same 
amount of time in academic research, I have not seen 
major differences in the scientific behaviour and the 
desire to conduct good research between representati-
ves from each sector. Bias does exist both in academia 
and in the pharmaceutical industry, as people become 
emotionally attached to the hypothesis they formulate. 
Confrontations of opinions during the writing process 
enrich the scientific debate and the discussion section 
of manuscripts.
Industry researchers should continue to co-author 
publications of their research and take ownership and 
responsibility for the scientific content of manuscripts. 
Excluding industry researchers from authoring publi-
cations would not be ethical if they meet authorship 
criteria. In addition, promoting scientific McCarthysm 
could enhance ghost-writing, carrying the risk of further 
disconnecting authorship from responsibility.
One traditional way to make up COI is what has been 
called the “non-writing author/non-author writing syn-
drome” (34). This syndrome has two main characteris-
tics: an employee of a drug company or a professional 
medical writer, who will not appear as a named author, 
writes the manuscript of a scientific publication based 
on material provided by the company. The non-writing 
author, who is usually a well-known expert in the field 
(“a busy key opinion leader”), is offered authorship of 
the paper. This non-writing author is supposed to lend 
an air of scientific credibility to the work. Although 
medical writing support may be useful to edit manu-
scripts originally written by non-professional writers, 
full ghost-writing poses several problems: first it may 
be used to mask or to undermine COI, secondly, it may 
promote disconnection of authorship from responsi-
bility. When the manuscript is entirely written by a 
“non-author writer”, two patterns emerge in practice 
(Table II): some non-writing authors may be tempted 
not to check scrupulously the work against the original 
data. Alternatively, some non-writing authors read the 
manuscript carefully and make important contributions 
to the content. It is the responsibility of the authors to 
Table II. Authorship patterns for clinical studies sponsored by the pharmaceutical industry
The scientific investigator The busy ”key opinion leader”
•	 Participates in the major steps of the study: protocol generation, patient 
recruitment, data analysis and manuscript writing.
•	 relies on a co-investigator who will substitute for him or her in all 
stages of the trial.
•	 Analyses the results carefully and requests to be provided with complete 
data sets.
•	 relies on the material provided without making any change or comment.
•	 quickly reviews the manuscript written by a professional medical writer. 
Corrects his or her affiliation/title.•	 Participates in manuscript writing and critically reviews content versus 
key tables, analysis plan and protocol.
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be guarantors of the data presented, and when the ma-
nuscript has been written by somebody else it is a real 
challenge to take full responsibility for the results and 
to control the way they are presented.
Although the industry has been made entirely respon-
sible for the “non-writing author/non-author writing 
syndrome”, researchers outside the medical field have 
expressed different opinions: Trudo lemens, from the 
Faculty of law of Toronto, has suggested that medical 
researchers are accustomed to operating in a culture 
where authorship is not strictly determined on the basis 
of true contribution, making the acceptance of ghost-
writing easier: “the line between adding one’s name 
to an article written by a junior researcher and adding 
one’s name to an article prepared by a medical writers’ 
bureau seems narrow” (35).
Manuscript content versus original research
A manuscript is usually a selection of data from a 
prospectively planned research project that was sup-
ported by a protocol, a statistical analysis plan and a 
set of results (statistical tables, listings and a study 
report). Data selection for manuscript preparation is 
a very sensitive process which is prone to major bias, 
especially when the results do not meet expectations. 
For example, the temptation may sometimes be high 
to overemphasize a “positive” exploratory analysis at 
the expense of a “negative” primary end-point. Unfor-
tunately, most often reviewers and readers do not have 
access to the original study material and, as a result, 
they may ignore the data selection process. Even aut-
hors did not have access to the original data in the past 
in some instances. It is surprising to realize that some-
times the data presented in a scientific publication are 
different from the data presented in the original report. 
To illustrate this point, I have taken the example of a 
recently published clinical trial on a biological agent 
in psoriasis (36). Table III shows, in the right-hand 
column, the original data as presented to the Food and 
Drugs Administration and publicly available on the US 
drug label (37). Data from the same study as disclosed 
in the manuscript are presented in the left-hand column. 
It is striking to realize that there are major differences 
between the two sets of data. This suggests that the 
study was published without disclosing the results for 
the prospectively planned primary end-point. 
Suggestions on how to better ensure reporting of clinical 
trials and scientific research
Following the recommendations from the ICmJE and 
other researchers, significant efforts have been made 
by drug companies concerning prospective registra-
tion of drug trials and commitments to publish study 
results. The focus should now be on ensuring accurate 
publication of study results. 
A system of checks and balances is required to en-
sure transparency both for “industry-sponsored” and 
“academic medical” research. Suggested principles to 
minimize the impact of financial COI on how study 
results are reported include: 
•	 ensure adherence to standards for research conduct 
and reporting: a prospectively defined protocol and 
a statistical analysis plan should be made availa-
ble to editors and reviewers, the principle of an 
independent data monitoring board for multicentre 
studies should be generalized;
•	 complete registration of clinical trials as recommended 
by the ICmJE with commitment to publish results;
•	 definition of authorship based on actual contri-
bution to study design, execution, reporting and 
manuscript writing, possibly defined by the inde-
pendent data monitoring board or an independent 
publication committee;
•	 full disclosure and discussion of COI (financial and 
academic) for authors and reviewers;
•	 submission of the core study material (protocol, 
statistical analysis plan, statistical tables and clinical 
study report) alongside the manuscript for all clinical 
studies (to allow trained reviewers to assess the im-
pact of COI on how research results are reported);
•	 creation of international guidelines for systematic 
evaluation on how study results are reported in ma-
nuscripts to help reviewers. These principles should 
apply to both academic and industry-sponsored 
research. The current peer review process for ma-
nuscripts is not sufficient to prevent reporting bias 
and there is a need for a more stringent independent 
Table III. Reporting of efficacy data: differences between drug package insert and scientific publication (from 36, 37)
End-point Scientific publication US package insert
PASI 75 ”At any time during the study”
•	 Alefacept: 33%
•	 Placebo: 8%
”2 weeks post-dosing”
•	 Alefacept: 21%
•	 Placebo: 5%
Psoriasis Global Assessment ”Clear or almost clear”
•	 Alefacept: 24%
•	 Placebo: 8%
”Clear or almost clear”
•	 Alefacept: 14%
•	 Placebo: 5%
maintenance of effect ”Of the patients who achieved at least 75% PASI reduction 
2 weeks post-dosing, 71% maintained at least 50% 
improvement in PASI for 12 weeks.”
25 of the 166 patients randomized to Alefacept 
maintained at least 50% improvement in PASI for 12 
weeks.
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control on how biomedical research findings are 
communicated. 
The challenge ahead of us is certainly enormous, 
but there is no other option to optimally serve patients 
who have dedicated their time and effort to participate 
in clinical research.
4. The eDiTor’s perspeCTive
Anders Vahlquist 
Throughout the history of science, conflicts of interest 
(COI) have been an inherent problem in medical re-
search and thus for medical journals too, which, in the 
best of worlds, should be the guarantors of propagating 
correct and unbiased information in the best interest 
of the patients and the general public. However, it is 
only recently that matters of COI have become a daily 
priority for editors of medical journals; one reason is 
the emerging public interest in these issues, another is 
the increased awareness of how important economic 
decisions in the healthcare sector may be influenced 
by biased scientific reports originating from compa-
nies selling drugs or medical devices. For an editor 
the mere fact that the reputation of his or her journal 
may be jeopardized by one or two flawed papers is 
reason enough to scrutinize these matters. It is not 
surprising therefore that issues related to COI have 
been discussed in several recent editorials in general 
medical journals (12, 38–40) and two from the field of 
dermatology (2, 5).
The scope of conflicts
Scientific publications reporting the results of clini-
cal trials of drugs or medical equipment are notori-
ously liable to judgement bias. This necessitates strict 
guidelines, not only on the design of the study and how 
to document the results, but also on how to disclose any 
spurious impact of COI in the authors’ interpretation 
of the results. Needless to say, COI may also be “hid-
den” in clinical studies that do not have any company 
support. For example, a description of a new diagnostic 
or therapeutic procedure may represent a COI if the 
new procedure is virtually impossible to perform el-
sewhere and that specific medical centre depends on 
revenues from additional patient referrals. For all these 
reasons it is imperative that a medical journal has clear 
guidelines, like those established recently by the 
Journal of the American Medical Association (JAMA) 
(39), on how to disclose COI in submitted papers. 
More subtle conflicts, such as a tendency of many in-
vestigators to favour a presentation of positive instead 
of negative findings, is more difficult for journals to 
control, and must rely on authors’ integrity as well as 
good scientific training and ongoing ethical discussion 
at the various academic research institutions.
How to disclose conflicts 
All papers (also case reports that include a new therapy) 
should contain a statement about COI. It is advisable 
to highlight this under a separate heading, or under 
Acknowledgement. Such a policy should also apply 
when the editor submits a paper to his/her own journal 
(as author or co-author). In this situation it is advisable 
that an assistant editor is appointed, who then takes 
full responsibility for the review process and makes 
the decision about publication without any interference 
from the editor. This precaution against COI and self-
interest can be highlighted in a footnote if the paper is 
subsequently published.
Some other questions that all journal editors should 
address in relation to COI are summarized in Table 
IV. 
Conclusion
Disclosure of COI is a sine qua non for a medical journal, 
and awareness of COI should influence all aspects of the 
review process. The reputation of a journal can be da-
maged if a published study is later brought into question 
on the grounds of undeclared financial COI, especially 
if the intervention has implications for the wellbeing 
of patients and for the cost of health services.
Starting with the selection of an unbiased section 
editor for each paper, he or she should in turn select 
peer reviewers without any known strings to the aut-
hors or study sponsor, and without competing financial 
interests. A declaration of COI is obligatory for the 
authors, but should also be considered for the refe-
rees. The question remains as to how an editor can be 
sure that self-declarations of COI are correct without 
Table IV. Key questions that journal editors need to address in 
relation to conflicts of interest (COI)
• Has the journal's policy on conflicts been clearly declared?
• How do you ensure that authors with conflicts declare them?
• Should all reviewers also disclose their COI? What about "hostile" or 
"too friendly" reviewers who might have a COI?
• Should the determination of whether or not a conflict exists be in the 
hands of the potentially conflicted or should he or she simply report all 
potential kinds of COI that come to mind?
• Should papers on drugs or medical devices which are co-authored by 
industry people always be regarded as potentially biased and hence be 
treated differently in the review process?
• Do you suspect ghost writing by a drug company or an academic 
related to a certain commercial product without stating clearly that this 
is the case?
• In the case of drug-company sponsored supplements, is a declaration 
of sponsorship at the front of the supplement enough, or should it be on 
each included article given that single key articles are often distributed 
at marketing events? (5)
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playing the role of a police officer. It is impossible to 
be completely thorough in this respect, because cross-
examinations and filing of legally reliable documents 
are something most of us do not want to see as part of 
a peer review process.
If authors violate the guidelines and are later proven 
to have given false or incomplete statements about COI 
should this lead to disciplinary action by the editor? One 
medical journal recently decided to deny authors who 
violate the disclosure policy the privilege of publishing 
their work in that journal for up to two years (4). There 
will hardly be a consensus about such rules among dif-
ferent journals, but these matters need to be discussed 
thoroughly at journal editorial boards. The message is 
clear: editors must take disclosure of relationships that 
might influence article content very seriously.
5. effeCTs of DeCLareD ConfLiCTs of 
inTeresT on reaDers’ perCepTions
Sara Schroter
Despite growing evidence that authors’ conclusions 
are influenced by conflicts of interest (COI) (3, 41, 
42), little is known about how declarations of COI 
influence readers’ perceptions. The British Medical 
Journal (BMJ) has long been interested in investigating 
the effects of COI, and for this reason conducted two 
randomized controlled trials (43, 44). The first (43) 
involved sending a paper to a random sample of 300 
BMJ readers and asking them to rate the study in terms 
of interest, importance, relevance, validity, and believa-
bility, using a series of 5-point likert scales. All readers 
received the same paper, which described the impact of 
pain from Herpes zoster on patients’ daily functioning, 
and they were randomized to one of two groups. The 
first group (financial COI group) received the paper 
with a declaration that the authors were employees of 
a company and potentially held stock options in this 
company. The second group received the paper with a 
statement that the authors had no COI (none declared 
group). A total of 170 readers responded and t-tests 
showed readers in the financial COI group thought that 
the study was significantly less interesting, important, 
relevant, valid, and believable than readers in the none 
declared group (p < 0.05). 
The BmJ team then conducted a further randomized 
controlled trial using similar methods to evaluate the 
impact of the type of COI on ratings of interest, im-
portance, relevance, validity, and believability; and to 
assess the influence of the type of paper on this effect 
(44). We introduced a third type of COI statement with 
a declaration that one of the authors was a recipient of 
funding for studentships and research grants from the 
company (grants COI group). The clinical impact paper 
from the first study was used again, together with a more 
general one describing the use of problem lists for letters 
between hospital doctors and general practitioners. A 
total of 450 readers were randomized to receive each 
paper, with 150 in each of the three COI groups. The 
analysis of variance showed that overall, importance, 
relevance, validity, and believability ratings were 
significantly lower in the financial COI group than in 
the none declared group (Table V). Validity ratings for 
the financial COI group were also significantly lower 
than for the grants COI group. There were significant 
differences in the ratings between papers for all five 
measures (p < 0.001), with the paper about problem lists 
scoring significantly higher. A significant inter-relation 
was observed between COI and type of paper for the 
two measures interest (p = 0.012) and believability 
(p = 0.007). For these measures the lower ratings for the 
financial COI group were more pronounced for the paper 
describing the impact of pain from Herpes zoster.
These two studies show that the declaration of finan-
cial COI can have a significant effect on readers’ per-
ceptions of the scientific credibility of some published 
research. The disclosure of authors’ conflicts of interest 
is important and all journals should actively enforce this. 
One could argue that the results of these studies might 
encourage the concealment of “potentially negative” 
COIs through authors fear of their research being di-
scredited. However, I see these results as positive in the 
sense that readers are now paying attention to the actual 
wording of COI statements and assessing the integrity 
of reported research in light of these declarations. The 
size of the effect depended on the type of financial COI 
reported and the type of paper. 
Table V. Scorea distributions for readers’ perceptions of papers 
with and without declaration of various types of conflict of interest 
(COI). Analysis of variance results: mean values and significance 
levels relating to competing interest
Conflict of interest (COI)
Scored variable None declared 
group (n = 174) 
Financial COI 
group (n = 192) 
Grants COI 
group (n = 156) 
p-value
Interest 3.21 3.06 3.26 0.12 
Importance 3.29 3.03 3.16 0.035b
relevance 3.44 3.13 3.35 0.009b
Validity 3.16 2.82 3.12 < 0.001c
Believability 3.49 3.20 3.36 0.025b
alow scores indicate low interest, importance, relevance, validity, and 
believability.
bRating for financial COI group significantly lower than that for none 
declared group.
cRating for financial COI group significantly lower than that for none 
declared group and for grants COI group.
This table is reproduced from BmJ paper (44) with permission.
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deriving credibility from their associations with pro-
fessionals and PSGs, both allegedly used as “fronts” 
(49, 50). The increasing use of disease awareness 
campaigns (DACs) has provoked rising concern among 
regulatory bodies, consumer organizations and politici-
ans. Some have been condemned as disease mongering: 
the corporate construction of disease and its impact on 
health and well-being, in well-orchestrated strategic 
initiatives targeting public, patient and/or professional 
audiences (51). These offer credible channels of com-
munication with relevant decision-makers, securing 
market rewards for the companies. marketing/Pr 
executives thus deploy a “third party technique” 
distancing company messages from themselves, who 
might be seen as self-interested messengers. PSGs and 
so-called key opinion leader (KOl) professionals are 
therefore crucial to the legitimization of campaigns. 
A company first to market a drug, wishing to sustain 
market leadership by differentiating their product from 
that of competitors’, or by developing a new condition 
for that drug, would have good reasons for DAC invol-
vement (52). A British Parliamentary Select Committee 
recently feared that DACs, and thus PSGs, had become 
no more than marketing tools for the pharmaceutical 
companies (53). 
Company-prompted and sponsored “research” sur-
veys of patient experience, and focus-group-based stu-
dies have become an increasingly common component 
of DACs, deriving legitimacy from representation as 
PSG initiated or approved projects. Authenticity can be 
reinforced by the involvement of KOl professionals. 
Sadly, the methodology involved can be questionable 
in design, execution, and in analysis/interpretation and 
selective presentation of results. Also prominent in 
DACs are “real patients”, often “supplied” by PSGs or 
doctors (with consent) whose experience has allegedly 
included delayed diagnosis/consultation, lack of or 
old-fashioned treatment, or denial of innovative treat-
ment needlessly harming quality of life. most DACs 
also involve emotional appeals, mounted via carefully 
placed “human interest” media stories, directed towards 
securing public sympathy and official support and re-
sources; and to prompt product demand and compliance 
from patients.
Regulation of the relationships between patient support 
groups, health professionals and industry
The circumstances surrounding PSG/professional/
company mutual imvolvement in DACs are growing 
in complexity; becoming increasingly cross-national, 
and global in their design and impact. much of the 
substance of a DAC may be presented via the inter-
net, and media events outside a given “home” market. 
Crossing cultures and regulatory jurisdictions, they are 
more difficult to influence, monitor and regulate. PSG 
6. paTienT supporT groups anD ConfLiCTs 
of inTeresT
Ray Jobling 
Relationships between the pharmaceutical industry and 
patient support groups
Patient support groups (PSGs) for people with skin 
disorders have a long history. For example, Psoriasis 
Associations have existed for decades (45). most PSGs 
levy subscriptions and seek donations and legacies, and 
a few enjoy government support. Some have sizeable 
endowments, thereby securing income to finance their 
activities. The UK’s Psoriasis Association has contribu-
ted more than £2 million towards research. Funding PSG 
operations, however, represents an ever-present diffi-
culty. Paradoxically, better performance further raises 
expectations, with attendant higher costs. Partnerships 
and joint projects with pharmaceutical companies may 
therefore seem attractive. many PSGs seek corporate 
members, sponsorship and advice (websites, meetings, 
travel, etc.). Such assistance is valuable: without it many 
organizations could not survive, let alone thrive. 
There is, nonetheless, a danger of dependency and 
undue influence in what is a relationship of unequals 
(46). Theoretically, both companies and PSGs should 
co-operate on the basis of clear values, transparency and 
accountability, with explicit mutually-agreed ground 
rules. many accept voluntary codes of self-regulation, 
beyond legal requirements protecting the public interest. 
The Association of the British Pharmaceutical Indus-
try has its own Code, and PSGs and companies now 
commonly reach formal bilateral agreements covering 
the terms upon which any joint initiative is founded. 
Nevertheless, the relationship between the dermatologi-
cal industry, health professionals and PSGs has become 
the subject of critical scrutiny (47). The UK codes, for 
example, have been criticized by a Parliamentary Com-
mittee as weak and ineffectual (48), a concern echoed 
in a current Consumers International report (5) on 
the ABPI Code. New Codes proliferate however. One 
governs 10 companies and 40 or so PSGs, including 
skin organizations, affiliated to the Health Coalition 
Initiative. British skin PSGs are also members of The 
Skin Care Campaign, which works with dermatology 
professionals to advocate the needs of all skin patients, 
alongside closely associated political “lobbying” by 
a registered All-Party Parliamentary Group on Skin. 
Both draw principal funding from the industry, thereby 
attracting criticism, but argue the formal transparency 
of their operation and abstraction and distance from the 
interests of individual companies
Disease awareness campaigns and “disease mongering”
One major focus has been political “lobbying”, with 
allegations that companies pursue self-interest while 
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efforts to deal with company and marketing executives 
nationally can be undermined by the fact that strategy 
and tactics, substance and style of both messages and 
delivery can ultimately be determined perhaps at re-
motely placed international corporate levels as part of 
global marketing strategies. Claims to legitimacy come 
from the involvement of international steering groups, 
including both patients and doctors, but without any 
framework of formal accountability. 
National voluntary regulatory codes are arguably 
inadequate in the face of such internationalization. 
Companies have increasingly elaborated their patient 
relations and patient organization liaison strategies to 
engage with international PSGs and/or federations. But 
the latter’s organizational cultures and structures, and 
internal political dynamics do not always ensure that 
the subtleties of national perspectives, concerns and 
interests (including crucially regulatory requirements) 
are fully acknowledged. Anxieties have also been voiced 
about the absence or ineffectiveness of international 
(e.g. EU) safeguards, scrutiny and regulation.
Understandably, corporate approaches to PSGs con-
cerning joint initiatives and offers of financial aid are 
founded upon calculation of interest and the prospect of 
financial returns. The principal business of businesses 
is naturally to do business, notwithstanding their broa-
der concern to be “good citizens”. PSGs operating in a 
field where there is a common chronic disease and more 
widespread expressions of it, do so in a sizeable market 
of major commercial significance. They can “enjoy” the 
benefits of industry interest, as can relevant professio-
nals, applying welcome resources to positive purpose. 
Those speaking for rarer conditions and/or varieties 
affecting far fewer “consumers” are less fortunate. Of-
fering no obvious “bottom line” financial advantage they 
can be deemed less worthy of corporate “investment”, 
in funding research, awareness raising and lobbying. 
Here innovation is slow, and public knowledge and 
understanding lacking. Tellingly, company-supported 
DACs frequently ignore these completely. Another 
outcome is financial inequity in the circumstances of 
different PSGs (and research groups), sadly not always 
recognized by better-off organizations. Federal or col-
laborative organizations, which do seek to advocate for 
skin disorders in general (such as the UK’s Skin Care 
Campaign) rather than solely concentrating on common 
conditions with associated large markets, are therefore 
important.
Globalization?
International PSG federations can share experience 
and work to counter inequity, addressing the risk that 
those in poorer economies receive less and worse care. 
They can do so by mutual encouragement, transferring 
expertise and skills, building capacity, launching joint 
initiatives, and potentially lobbying at the level of 
international agencies and authorities. However, such 
federations have encountered financial problems, and 
potential COI. recent experience with the European 
Federation of Psoriasis Associations (EUrOPSO) has 
suggested that there can be major risk of dependency 
stemming from over-reliance on corporate support, 
even supposing the innocent intent of those providing 
funds. EUrOPSO’s recent efforts to agree a formal 
co-operative arrangement with a company stalled, 
according to a report to member organizations, when 
that company encountered regulatory “adversities” in 
relation to a specific new product (54). This, reportedly, 
radically changed the original plans and led to difficul-
ties, further deepened by a company merger. resumed 
negotiation produced sponsorship terms granting “sole” 
leadership for an initial year, and a position as “lead 
corporate sponsor” thereafter. In return, the company 
and EUrOPSO would use each other’s logo on their 
websites. member associations would be advised that 
the company’s dermatology portfolio would be develo-
ped on the basis of registration of a class of treatments. 
An opportunity to include information/promotional 
material in a EUrOPSO membership mailing was men-
tioned. Other co-sponsors subsequently came forward. 
A plenary session of the Federation in 2004 heard, 
nonetheless, that full organizational and operational 
independence could not be assured, since perceived 
corporate perspectives, sensibilities and interests could 
provide the framework for the Federation’s agenda, 
priority setting and decision-making, because the fun-
ding base rested virtually wholly on corporate support 
(55). It was decided that the incoming Executive must 
be mandated to consider first principles, address the 
risks of COI, and to report back on the appropriate basis 
for future relationships between EUrOPSO and corpo-
rate partners. more than a year later, despite repeated 
follow-up questions, no progress had been reported. 
World Psoriasis Day
The launch of the World Psoriasis Day (WPD) initiative 
and the related Psoriasis Disease Awareness Campaign 
was arguably originally prompted by corporate efforts 
to launch and promote the virtues of the new biological 
agents for treating severe psoriasis. The date chosen for 
the first WPD coincided in England with a crucial stage 
in National Institute of Clinical Effectiveness (NICE) 
assessment of biologicals, raising questions of appro-
priateness for the Psoriasis Association, as well as wider 
concerns surrounding campaign content. The Association 
therefore took no part in the “Day”, and came to a natio-
nal agreement with the corporate sponsor (instructively 
without needing reference to the independent interna-
tional steering committee) that the first WPD/campaign 
would have no direct publicity in the UK. 
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The planning and organization of the second WPD, 
and a widening of the DAC, drew the International 
Federation of Psoriasis Associations into official 
“ownership” of the campaign, conveying valuable cre-
dibility. Other companies now also participate. The 
WPD website directed towards securing wider indu-
stry campaign involvement promises companies the 
enhancement of “leverage/influence” over it. Earlier, 
it has listed certain advantages in company commit-
ment: improvement towards expanding the market for 
psoriasis treatments; brand revitalization; monitoring 
competitors; ensuring visibility and extensive media 
reach. It has also stressed the opportunity to become 
a familiar name with patients either newly seeking or 
returning to a treatment regimen. WPD represents, it 
was said, an opportunity to any company seeking to 
make a name in psoriasis. Involvement would enable 
staff to establish and/or maintain a brand’s name in the 
minds of people with psoriasis/psoriatic arthritis – with 
obvious corporate benefits. It was noted in justification 
of WPD involvement, that it could also help company 
products in current early phase development. By fully 
integrating a pre-market strategy with WPD, it could 
be used to create greater awareness amongst important 
target audiences – eventual adapters of development 
products. A chance to “give something back”, and to 
thank patients has also been mentioned.
A challenge? 
There are indisputable issues of principle at stake in 
the close, increasingly interdependent engagement of 
skin PSGs, dermatological professionals and industry. 
It is a potentially unequal relationship given the latter’s 
considerable financial and organizational resources 
and global reach. There are good reasons for concern 
about dependency and its implications. It is not unre-
asonable to ask whose hands are strategically shaping 
perspectives, determining issues and priorities, and 
setting the terms of public debate. PSGs need to find 
and speak with their own distinctive patient voice. 
Even dermatologists must recognize and respect the 
importance of patient/PSG autonomy in their accounts 
of experience, expression of problems and needs and 
suggested solutions. As to campaigning/lobbying, PSGs 
rely for their effectiveness upon trust, particularly of 
those they try to serve and represent, but also of the 
wider public, agencies and governments they seek 
to influence. Interests demand acknowledgement; 
transparency and accountability need consideration; 
potential conflicts must be addressed. Unquestionably, 
close working relationships add value and represent 
significant social capital, but confidence and trust will 
come from collective self-awareness, openness, and 
the adoption of transparent principles encouraging 
sound practice and underpinning all joint working. 
Naturally, regulatory frameworks are also essential, but 
the globalization of financially substantial market and 
corporate activities in dermatology, and of organized 
patient support, represents a challenge. Dermatology 
lags behind many other specializations in attending 
explicitly to the essential issues.
7. Where Do We go froM here?
Hywel Williams
Some rays of hope
The most important point to glean from these com-
mentaries is simply to be more aware of conflicts of 
interest (COI) in dermatology. Awareness of what it 
is, how it can influence behaviour amongst clinical 
colleagues, academic key opinion leaders, and even 
amongst disease awareness campaigns “organized” 
by patient support groups. Terms such as “ghost-writ-
ing” and “disease mongering” should now part of the 
dermatologists’ vocabulary, and they need to be taught 
and understood by those training in dermatology. 
Even though some of the material described by the 
contributors to this compilation might seem difficult 
to overcome, some simple steps have already been ta-
ken by the academic community to minimize financial 
conflicts. These steps have been especially noticeable 
with regards to the publishing of randomized controlled 
trials, which are so often the cornerstone of determining 
whether a new product makes it in the marketplace. In 
addition to clearer and more consistent dermatology 
journal and conference policies for dealing with and 
declaring COI appropriately, these measures include:
•	 The principle of prospective trial registration – to 
ensure that a protocol containing a declaration of 
the primary outcome measure and analysis plan 
is deposited in a publicly accessible trials register 
before publication. many journals belonging to the 
International Committee of medical Journal Editors 
(ICmJE) now insist that trials need to be registered 
before they can be even considered for publication 
(56, 57).
•	 Better reporting of clinical trials within journals by 
following the CONSOrT (www.consort-statement.
org) reporting recommendations to ensure that all 
essential trial data, such as how randomization 
was generated and concealed, how blinding was 
achieved, how many patients entered the study 
and how many were analysed etc are included, so 
that readers can quickly assess the validity of that 
published study (58).
•	 Systematic reviews, such as those produced by the 
Cochrane Collaboration, that attempt to produce 
unbiased summaries of trial evidence (59).
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The need to be less coy about COI
It is clear that the problem of COI in dermatology really 
does exist and that the answer to the problem belongs 
to us all – clinicians, researchers, industry, editors, 
ethics committees, academic institutions and patient 
support groups. Brennan and colleagues (12) state that 
self-regulation has not satisfactorily protected the inte-
rests of patients so far, and suggest that more stringent 
regulation is necessary, including the elimination or 
modification of common practices related to small gifts, 
pharmaceutical samples, continuing medical education, 
funds for physician travel, speakers’ bureaus, ghost-
writing, and consulting and research contracts. They 
propose an interesting idea whereby academic centres 
take a lead in addressing such issues – only time will 
tell if academic centres are up to the challenge. 
I wish to emphasize that the aim of these commen-
taries is not to discourage a flourishing and innovative 
healthcare industry, but to ensure that processes are in 
place in proportion to need that ensure that COI are 
addressed fairly and openly. It is time for the taboo of 
COI in dermatology to be broken and for all concerned 
with its effects – including the public – to begin open 
discussions. That time is now – or else we risk losing 
the very foundation of values on which the dermatology 
profession is built (Fig. 3). 
Conflicts of interests
Hywel C. Williams has no financial conflicts with any for-profit 
organization.
Luigi Naldi: the GISED Study Centre is funded by AIFA to co-
ordinate the Psocare project in Italy. In 2004, the GISED Study 
Centre received a grant from Serono to conduct a survey of 
psoriasis in Italy. During the last 3 years he has been a speaker 
at some industry-sponsored symposia on psoriasis.
Carle Paul is a former employee of the Clinical research De-
partment, Novartis Pharma, Basel Switzerland.
Anders Vahlquist is the Editor of this journal. 
Sara Schroter works for the British medical Journal, which 
supported her research into conflicts of interest. She does not 
have financial conflicts of interest to declare.
Ray Jobling does not have any financial conflicts with any 
for-profit organization. 
rEFErENCES
1. Bartus Cl, Katz KA. Advertising in dermatology journals: 
journals’ and journal editors’ policies, practices, and attitu-
des. J Am Acad Dermatol 2006; 55: 116–122. 
2. Goldsmith LA. Conflict of interest and the JID. J Invest 
Dermatol 2006; 126: 1–2.
3. Perlis CS, Harwood m, Perlis rH. Extent and impact of 
industry sponsorship conflicts of interest in dermatology 
research. J Am Acad Dermatol 2005; 52: 967–971. 
4. Prendergast mm, Abramovits W, Boguniewicz m, lebwohl 
M, Tokar M, Tong KB. Look beyond financial conflicts of 
interest in evaluating industry-academia collaborations in 
burden-of-illness and outcomes research studies in derma-
tology. J Invest Dermatol 2004; 123: 452–454. 
5. Eedy DJ, Graham-Brown RA. Ethics and conflicts of interest 
in the BJD. Br J Dermatol 2004; 151: 1–2. 
6. Brunne V, mertins G, reimann G, Brockmeyer NH. Off-
label use in dermatological practice. The conflict between 
professional duty and legal requirements) Hautarzt 2004; 
55: 727–734. 
7. Sams Wm, Freedberg Im. The dermatology-industry inter-
face: defining the boundaries. J Am Acad Dermatol 2000; 
43: 550–554. 
8. Blank IH. Industry-funded dermatologic research within 
academia in the United States: fiscal and ethical conside-
rations. J Invest Dermatol 1992; 98: 265–268.
9. Statement on BMJ conflict of interest policy. Available from: 
http://bmj.bmjjournals.com/cgi/content/full/317/7154/291/
DC1 (accessed August 29th 2006).
10. landefeld CS, Chren mm. Drug companies and information 
about drugs: recommendations for doctors. Characteristics 
of materials distributed by drug companies: four points of 
view. J Gen Intern med 1996; 11: 642–644. 
11. Chren mm. Interactions between physicians and drug 
company representatives. Am J med 1999; 107: 182–183.
12. Brennan TA, rothman DJ, Blank l, Blumenthal D, Chi-
monas SC, Cohen JJ, et al. Health industry practices that 
create conflicts of interest: a policy proposal for academic 
medical centers. JAmA 2006; 295: 429–433.
13. Wazana A. Physicians and the pharmaceutical industry: is 
a gift ever just a gift? JAmA 2000; 283: 373–380.
14. Mullis K. Dancing naked in the mind field. New York: 
Pantheon Books, 1998.
15. Horton R. The dawn of McScience. New York Rev Books 
2004; 514: 7–9.Fig. 3. Is this the new face of modern dermatology?
Acta Derm Venereol 86
497Conflicts of Interest in Dermatology
16. Angell m. The truth about drug companies: how they de-
ceive us and what to do about it. New York: Random House, 
2005: 336.
17. Kassirer JP. On the take: how medicine’s complicity with 
big business can endanger your health. New York: Oxford 
University Press 2004: 251.
18. Smith r. medical journals are an extension of the marketing 
arm of pharmaceutical companies. PloS med 2005; 2: 138. 
Epub 2005 may 17. 
19. Naldi l, Svensson A, Diepgen T, Elsner P, Grob JJ, Coen-
raads PJ, et al. European Dermato-Epidemiology Network. 
randomized clinical trials for psoriasis 1977–2000: the 
EDEN survey. J Invest Dermatol 2003; 120: 738–741. 
20. rochon PA, Gurwitz JH, Simms rW, Fortin Pr, Felson DT, 
minaker Kl, et al. Study of manufacturer-supported trials 
of nonsteroidal anti-inflammatory drugs in the treatment of 
arthritis. Arch Intern med 1994; 154: 157–163.
21. lexchin J, Bero lA, Djulbegovic B, Clark O. Pharmaceuti-
cal industry sponsorship and research outcome and quality. 
BmJ 2003; 326: 1167–1170.
22. melander H, Ahlqvist-rastad J, meijer G, Beermann B. Evi-
dence b(i)ased medicine--selective reporting from studies 
sponsored by pharmaceutical industry: review of studies in 
new drug applications. BmJ 2003; 326: 1171–1173.
23. Naldi l. A new era in the management of psoriasis? Pro-
mises and facts. Dermatology 2005; 210: 179–181.
24. http://www.worldpsoriasisday.com/1_history/index.html
25. www.psocare.it
26. liberati A, magrini N. Information from drug companies 
and opinion leaders. BmJ 2003; 326: 1156–1157.
27. Garattini S, Bertele’ V, li Bassi l. light and shade in pro-
posed revision of EU drug-regulatory legislation. lancet 
2003; 361: 635–636. 
28. Gross CP, Gupta AR, Krumholz HM. Disclosure of financial 
competing interests in randomised controlled trials: cross 
sectional review. BmJ 2003; 326: 526–527.
29. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. 
Calcineurin inhibitors decrease DNA repair and apoptosis 
in human keratinocytes following ultraviolet B irradiation. 
J Invest Dermatol 2005; 125: 1020–1025.
30. Pediatric Advisory Committee of the Food and Drugs 
Administration. Washington DC February 2005. Transcripts 
of the meeting. Available from: www.fda.gov/ohrms/dock-
ets/ac/05/transcripts/2005-4089T2.pdf
31. Experimental lotion repairs sun damage. ABC news, may 
2003. Available from: http://www.agiderm.com
32. International Committee of medical Journal Editors criteria 
for authorship. Available from: http://www.icmje.org/
33. Buchkowsky SS, Jewesson PJ. Industry sponsorship and 
authorship of clinical trials over 20 years. Ann Pharma-
cother 2004; 38: 579–585.
34. Bodenheimer T. Uneasy alliance: clinical investigators 
and the pharmaceutical industry. N Engl J med 2002; 342: 
1539–1544.
35. Lemens T. Confronting the conflict of interest crisis in 
medical research. monash Bioethics review 2004; 23: 
19–40.
36. Alefacept package insert. Available at: www.fda.gov/med-
waTCH/SAFETY/2005/Amevive_PI.pdf.
37. lebwohl m, Christophers E, langley r, Ortonne JP, roberts 
J, Griffiths CE; Alefacept Clinical Study Group. An interna-
tional, randomized, double-blind, placebo-controlled phase 
3 trial of intramuscular Alefacept in patients with chronic 
plaque psoriasis. Arch Dermatol 2003; 139: 719–727.
38. Lipton S, Boyd EA, Bero LA. Conflicts of interest in 
academic research: policies, processes and attitudes. Ac-
countability in research 2004; 11: 83–102.
39. International Committee of medical Journal Editors. Uni-
form requirements for manuscripts submitted to biomedical 
journals. Writing and editing for biomedical publication. 
JAmA 1997; 277: 927–934.
40. Wechsler AD. Conflict of interest: what’s a journal to 
do? (Editorial). J Thoracic Cardiovasc Surg 2006; 131: 
771–772. 
41. Kjaergard ll, Als-Nielsen B. Association between com-
peting interests and authors’ conclusions: epidemiological 
study of randomised clinical trials published in BmJ. BmJ 
2002: 325: 249–252.
42. Als-Nielson B, Chen W, Gluud C, Kajegard ll. Association 
of funding and conclusions in randomised drug trials. JAmA 
2003; 290: 291–298.
43. Chaudhry S, Schroter S, Smith r, morris J. Does decla-
ration of competing interests affect reader perceptions: a 
randomised trial? BmJ 2002; 325: 1391–1392. 
44. Schroter S, morris J, Chaudhry S, Smith, r, Barratt H. 
Does the type of competing interest statement affect reader 
perceptions of the credibility of research? A randomised 
trial. BmJ 2004; 328: 742–743.
45. Coles r, Jobling r. Psoriasis associations. In: roenigk HH, 
Maibach HI, editors. Psoriasis. New York: Marcel Dekker, 
1985.
46. Herxheimer A. relationships between the pharmaceuti-
cal industry and patients’ organisations. BmJ 2003; 326: 
1208–1210.
47. HAI Europe, The ties that bind. Paris: HAI Europe, 1998 
(see also www.haiweb.org).
48. Which? magazine, Who’s injecting the cash? 24 April 2003.
49. House of Commons Select Committee on Health, 4th report 
on the Influence of the Pharmaceutical Industry – Section 
8: Disease Awareness Campaigns. HC42-I, 2005.
50. Consumers International. Branding the cure: a consumer 
perspective on corporate social responsibility, drug promo-
tion, & the pharmaceutical industry. london: Consumers 
International, 2006.
51.  moynihan r, Heath I, Henry D. Selling sickness: the phar-
maceutical industry and disease mongering. BmJ 2002; 324: 
886–891.
52. moynihan r. US seniors group attacks pharmaceutical 
industry ”fronts”. BMJ 2003; 326: 351.
53. Wang l-N. New ways to ensure patient loyalty. The Phar-
maceutical Journal 2004; 272: 635–636.
54. EUrOPSO. report on Operations, 2001–2004. 
55. Oral presentation of the report on Operation, 2001-2004.
56. Williams H, Goldsmith l. The JID opens its doors to 
high-quality randomized controlled clinical trials. J Invest 
Dermatol 2006; 126: 1683–1684.
57. Ormerod AD, Williams HC. Compulsory registration of 
trials. Br J Dermatol 2005; 152: 859–860.
58. Cox N, Williams HC. Can you COPE with CONSOrT? Br 
J Dermatol 2000; 142: 1–7.
59. Collier A, Johnson Cr, Delamere F, leonard T, Dellavalle 
rP, Williams H. The Cochrane Skin Group: promoting the 
best evidence. Journal of Cutaneous medicine and Surgery 
2005; 9: 324–331. 
Acta Derm Venereol 86
